Delnova

DelNova is creating innovative therapeutics by solving unmet medical needs using clinically validated molecules linked to advances in drug delivery (including drug targeting, drug administration and formulation enhancements). DelNova’s initial therapeutic focus will be improving the outcomes of neurotoxin therapies in aesthetic and overactive bladder with ReViVox®, patent-pending. DelNova is applying advances in drug delivery technology to create proprietary therapies. Meet DelNova’s Senior Management, Board of Directors and Scientific Advisors. The Company’s lead clinical candidate is ReViVox®, a patent-pending product for the rescue of complications caused by off-target muscle paralysis following aesthetic and medical neurotoxin therapies, specifically botulinum-Type A toxins (e.g. Complications after botulinum injections offer a large market where there is currently no effective or approved treatment. ReViVox® is being developed as rescue product that could potentially serve this growing neurotoxin market and accelerate its growth.